Medinotec Inc. Reports 24% Revenue Growth to $2.65 Million for Quarter Ending May 31, 2026

Medinotec Inc. reported its financial results for the quarter ending May 31, 2026, revealing a revenue of $2.65 million, a 24% increase from $2.13 million in the same period last year. The company achieved a gross profit of $1.31 million, up from $913,168, reflecting improved operational efficiency despite rising costs. Operating expenses surged to $1.13 million, primarily due to increased selling expenses, which rose significantly from $21,773 to $503,255, and higher general and administrative costs. The net income for the quarter was $222,014, compared to $113,784 in the prior year, resulting in a basic earnings per share of $0.02, up from $0.01.

The company’s balance sheet as of May 31, 2026, showed total assets of $6.99 million, an increase from $6.81 million at the end of February 2026. Current assets rose to $6.57 million, driven by higher accounts receivable and inventory levels. Notably, accounts receivable increased to $2.51 million, reflecting a strategic focus on expanding customer relationships, while inventory levels also rose to $1.43 million. The company’s total liabilities increased slightly to $1.13 million, resulting in total stockholders' equity of $5.85 million, up from $5.71 million.

Strategically, Medinotec has continued to focus on its core operations in the medical device sector, with significant revenue derived from its distribution agreements, which accounted for approximately 81% of total revenue. The company has also expanded its product offerings, having received FDA 510(k) clearance for its Outflo product in March 2025, which is expected to enhance its market position. The company’s operations are primarily based in South Africa and the United States, with ongoing evaluations for potential geographic expansion.

Operationally, Medinotec reported a notable increase in customer engagement, with 87% of its revenue for the quarter coming from a single customer, DISA Life Sciences, compared to 84% in the previous year. The company’s employee headcount remained stable, supporting its operational needs as it navigates the complexities of the medical device market. The company’s cash position decreased to $2.52 million from $2.76 million, attributed to cash used in operations and investments in property, plant, and equipment.

Looking ahead, Medinotec Inc. remains optimistic about its growth trajectory, driven by its strategic initiatives and product development efforts. The company plans to continue leveraging its existing customer base while exploring new market opportunities to enhance its revenue streams. Management is focused on maintaining operational efficiency and managing costs effectively to support profitability in the upcoming quarters.